Abstract
AbstractThermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant lesions most likely mediated by an anti-tumor immune response. Although microwave ablation (MWA) is increasingly substituting other ablative techniques, its systemic immunostimulatory effects are poorly studied. We analyzed tumor-specific immune responses in peripheral blood of HCC patients after thermal ablation with regard to T cell responses and disease outcome. While comprehensive flow cytometric analyses in sequential samples of a prospective patient cohort (n = 23) demonstrated only moderate effects of MWA on circulating immune cell subsets, fluorospot analyses of specific T cell responses against seven tumor-associated antigens (TTAs) revealed de-novo or enhanced tumor-specific immune responses in 30% of patients. This anti-tumor immune response was related to tumor control as Interferon-y and Interleukin-5 T cell responses against TAAs were more frequent in patients with a long-time remission (> 1 year) after MWA (7/16) compared to patients suffering from an early relapse (0/13 patients) and presence of tumor-specific T cell response (IFN-y and/or IL-5) was associated to longer progression-free survival (27.5 vs. 10.0 months). Digital image analysis of immunohistochemically stained archival HCC samples (n = 18) of patients receiving combined MWA and resection revealed a superior disease-free survival of patients with high T cell abundance at the time of thermal ablation (37.4 vs. 13.1 months). Our data demonstrates remarkable immune-related effects of MWA in HCC patients and provides additional evidence for a combination of local ablation and immunotherapy in this challenging disease.
Funder
Koeln Fortune Program/ Faculty of Medicine, University of Cologne
CAP-CMMC
Universitätsklinikum Köln
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference41 articles.
1. Ferlay J, Ervik M, Lam F, et al (2018) Global Cancer Observatory, Cancer Today, estimated number of new cases in 2018, worldwide, both sexes, all ages. In: Glob. Cancer Obs. Cancer Today. Lyon, Fr. Int. Agency Res. Cancer. https://gco.iarc.fr/today. Accessed 30 Oct 2018.
2. Galle PR, Forner A, Llovet JM et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
3. Herbold T, Wahba R, Bangard C et al (2012) The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma—indication, technique and results. Langenbeck’s Arch Surg 398:47–53
4. Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208
5. Poulou LS, Botsa E, Thanou I et al (2015) Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 7:1054–1063
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献